glp-1 ckd Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria GLP-1 and the kidney: from

My cholesterol and blood pressure are high

Selection of other glucose-lowering agents will be determined by the balance between the glucose-lowering efficacy and the side effect profile of the individual agents (see Table 1)

There have been post-marketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors, including FARXIGA

The speed of the rod rotation could be adjusted manually

Dendritic spine actin cytoskeleton in autism spectrum disorder

hazard ratios 1.54-1.95) Masseter domain patients saw their mean duration fall from ~20.1 2.9 weeks in controls to 17.3, 17.0, 16.7 and 16.2 weeks (hazard ratios 1.72-2.08) Sensitivity analysis suggested ~55% of the reduction in duration was attributable to synaptic modulation, ~30% to lean-mass decline, and ~15% to metabolic variability